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INTRODUCTION
G protein-coupled receptors (GPCRs)
were assumed to exist and function in the
plasma membrane as monomeric proteins
that became activated by binding of one
agonist ligand to one receptor molecule
(Bourne et al., 1990). However, although
previous findings based on rather indirect
measures such as radioligand binding had
suggested a direct interaction of two recep-
tors with each other (Limbird et al., 1975;
Ferre et al., 1991), it was the application
of a protein-protein interaction assay by
bioluminescence resonance energy trans-
fer (BRET) that revealed the phenomenon
of molecular proximity between beta2-
adrenergic receptors in living cells (Angers
et al., 2000). Since then, this topic has
been a major subject of research and
numerous in silico and in vitro stud-
ies have suggested expression of family A
GPCRs as homodimers and higher-order
homomers in heterologous expression sys-
tems. However, the demonstration that
reconstitution of a single beta2-adrenergic
receptor molecule into lipoprotein par-
ticles leads to efficient activation of G
proteins raised concerns about the func-
tional significance of family A GPCR
homomers (Whorton et al., 2007), and
this is currently a controversial topic (for
an extensive review on GPCR homod-
imers/homomers, see Milligan, 2013; see
also Bouvier and Hebert, 2014; Lambert
and Javitch, 2014).
Another fundamental yet relatively
independent question is that related to
expression of different GPCR subtypes
as heteromers. It is well accepted that
the family C GABAB receptor needs two
protomers (GABAB-R1 and GABAB-R2)
to reach the plasma membrane as a
functional dimeric receptor (Jones et al.,
1998; Kaupmann et al., 1998; White et al.,
1998). On the other hand, although multi-
ple lines of evidence indicate that family A
GPCR heteromers may exist, particularly
in tissue cultures (González-Maeso, 2011;
Ferre et al., 2014), only relatively recent
studies started to test this formulation in
whole animal models.
FAMILY A GPCR HETEROMERS IN
WHOLE ANIMAL MODELS
One of the main limitations of the clas-
sical techniques used to define GPCR
heteromeric formation is the trans-
lation of findings obtained in cellulo
into physiological or behavioral assays
in whole animal models. In this con-
text, co-immunoprecipitation is an
approach commonly used to examine
protein-protein interaction in native
tissue (Milligan and Bouvier, 2005).
GPCR antibodies are usually neither
specific nor sensitive and therefore val-
idation assays in knockout mice are
often required (Fribourg et al., 2011;
Moreno et al., 2012). Considering this,
it is also clear that demonstration of
co-immunoprecipitation in native tis-
sues does not imply the existence of a
heteromeric assembly, as they may form
part of same protein complex through for
example PDZ domain-binding motifs at
the end of the C-terminal tails of both
receptor types together with adaptor pro-
teins (Magalhaes et al., 2010). Remarkably,
there are only a few studies that have inves-
tigated GPCR heteromeric formation in
living animals, and due to the lack of
biophysical methods applicable to study
protein-protein interactions in preclinical
models, their experimental approaches
were mostly focused on signaling and
behavioral outcomes rather than on the
existence of molecular proximity between
different GPCR subtypes.
Although it does not measure molec-
ular proximity, an attractive approach
to define whether heteromeric formation
is involved in behavioral phenotypes is
the use of peptides that disrupt recep-
tor complex formation. These peptides
tested in vivo are usually selected accord-
ing to findings previously obtained in
heterologous expression systems. As an
example, it was demonstrated that the
Gs-coupled dopamine D1 receptor and the
Gi/o-coupled dopamine D2 form a recep-
tor complex that induces Ca2+ release via
a Gq/11-dependent pathway (Lee et al.,
2004), and that the region of Met-257—
Glu-271 (intracellular loop 3; D2IL3-29-2)
but not Asn-243—Ile-256 (intracellular
loop 3; D2IL3-29-1) of the dopamine D2
receptor can pull-down the dopamine
D1 receptor. Based on a Tat-tagged pep-
tide approach, it was shown that intrac-
erebroventricular administration of the
peptide D2IL3-29-2, which disrupts het-
eromeric formation between dopamine
D1 and D2 receptors in vitro, induces
antidepressant-like effects in rats (Pei et al.,
2010). More recent findings using serial
deletions and point mutations further
demonstrate that dopamine D1 receptor
carboxyl tail residues Glu-404 andGlu-405
are critical in mediating the interaction
with the D2 receptor, and that admin-
istration of a disrupting peptide Tat-D1
modulates depression-like behavior in rats
such as forced swim test (Hasbi et al.,
2014). A similar approach was used to
block the association as a GPCR heteromer
between the mu-opioid receptor isoform
MOR1D and the gastrin-releasing peptide
receptor (GRPR) in the spinal cord (Liu
et al., 2011). The authors demonstrated
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that the C-terminus of MOR1D is crit-
ical for MOR1D-GRPR heteromeric for-
mation. Using a Tat-fusion peptide, they
also found that a motif consisting of seven
amino acids of the MOR1D C-terminus
(RNEEPSS) attenuates morphine-induced
scratching, but not morphine-induced
analgesia.
The question of whether GPCR het-
eromers exist ex vivo has been addressed
using time-resolved Förster resonance
energy transfer FRET (TR-FRET) in
plasma membrane preparations of mouse
brain. It was found that the dopamine
D2 receptor and the ghrelin receptor
(GHSR1a) co-localize in mouse stria-
tum, hippocampus and hypothalamus
(Kern et al., 2012). When membrane
preparations from hypothalamus were
incubated with red-ghrelin (acceptor
fluorophore) and an anti-D2 recep-
tor antibody together with a europium
cryptate-labeled secondary antibody
(donor fluorophore), a significantly
TR-FRET signal was observed. Although
TR-FRET signal is eliminated in hypotha-
lamic membrane preparations of GHSR1a
knockout mice, which supports speci-
ficity, these findings were observed ex vivo
in plasma membrane preparations and
further investigation will be necessary
to confirm the existence of GHSR1a-D2
heteromeric formation in hypothalamus
in vivo.
Another indirect approach to test
whether GPCR heteromeric formation
affects behavioral phenotypes is the use
of chimeric constructs that according
to biophysical assays in tissue culture
do not form heteromeric complexes.
Examples include the 5-HT2A-mGlu2
heteromeric receptor complex (Gonzalez-
Maeso et al., 2008) and the MT1-MT2
melatonin heteromeric receptor complex
(Baba et al., 2013). Serotonin 5-HT2A
and metabotropic glutamate 2 (mGlu2)
receptors have been shown to form a
GPCR heteromeric complex in HEK293
cells. Using chimeric constructs, it was
demonstrated that three residues located
at the intracellular end of TM4 of mGlu2
are necessary to form a complex with
the 5-HT2A receptor (Ala-6774.40, Ala-
6814.44, Ala-6854.48) (Fribourg et al., 2011;
Moreno et al., 2012). Head-twitch is a
rodent behavior model induced by hallu-
cinogenic 5-HT2A agonist such as lysergic
acid diethylamide (LSD) and DOI (Hanks
and Gonzalez-Maeso, 2013). This behav-
ior requires expression of 5-HT2A receptor
in cortical pyramidal neurons (Gonzalez-
Maeso et al., 2007) and is absent in mGlu2
knockout mice (Moreno et al., 2011),
which supports that mGlu2 is necessary
for 5-HT2A-dependent behavioral events.
Using a virally-mediated (HSV) over-
expression approach, it was demonstrated
that the head-twitch response induced
by the hallucinogenic 5-HT2A recep-
tor agonist DOI was rescued in mGlu2
knockout mice over-expressing wild-type
mGlu2 in frontal cortex, and that this
did not occur in mGlu2 knockout mice
over-expressing mGlu2deltaTM4N—a
mGlu2/mGlu3 chimeric construct that
according to previous findings in vitro
and in cellulo does not form the 5-HT2A-
mGlu2 receptor heteromer (Moreno et al.,
2012). A similar approach was used to
investigate function of the MT1-MT2
melatonin heteromeric receptor com-
plex in vivo in mouse (Baba et al., 2013).
The electroretinogram (ERG), consist-
ing mainly of an a-wave and a b-wave,
is commonly used to assess retinal func-
tion. Using transgenic mice that express
MT2-P95L (mutant that does not form the
MT1-MT2 heteromeric receptor complex
in HEK293 cells), it was shown that con-
trol mice responded tomelatonin injection
with an increase in the amplitude of the
a-wave and b-wave, whereas MT2-P95L
did not.
Although these events have been pro-
posed to represent a demonstration of
GPCR heteromeric expression, thereby
suggesting a new target for drug design,
their conclusions in animal models were
based largely on indirect approaches that
measured phenotypes affected by manipu-
lations such as chimeric constructs or Tat-
tagged peptides that impact heteromeric
organization in vitro. Consequently, it
remains unclear as to whether different
GPCR subtypes exist in close molecular
proximity in vivo in whole animal models,
or alternatively if these phenotypes result
of signaling mechanisms that are inde-
pendent of GPCR heteromeric formation.
Detailed measurement of such molecular
proximity in vivo, as well as the processes
that control GPCR heteromerization in




Although a wealth of data from in vitro
and in cellulo models have established
the important role of GPCR heteromers
in mediating precise and distinct roles
in signaling cascades, their influence in
the establishment of complex behav-
ioral phenotypes remains to be fully
elucidated. For instance, certain physi-
ological and behavioral outcomes could
conceivably be altered in the presence
of peptides that according to in vitro
or in cellulo assays disrupt GPCR het-
eromeric assembly. Similarly, the use of
viral-mediated over-expression or trans-
genic animals could translate into animal
models previous findings with receptor
mutants that do not form heterocomplexes
in vitro or in cellulo. However, a more
precise understanding of such structural
assembly obtained in rodent models will
be necessary to fully define whether GPCR
heteromers exist and function in vivo.
Some of these strategies include the use
of FRET (McGinty et al., 2011) of BRET
(Dragulescu-Andrasi et al., 2011) imaging
of protein-protein interactions in living
mice.
An important challenge in the fields
of GPCR research and molecular pharma-
cology is to develop an integrated under-
standing of how various mechanisms
communicate with each other to ulti-
mately orchestrate the formation of het-
eromeric complexes between some but not
all GPCR subtypes. Potential mechanisms
that are critical for this interaction speci-
ficity include specific pairs of residues that
govern heteromeric formation, clustering
of GPCRs in membrane microdomains,
and crosstalk between receptors and a
plethora of multidomain scaffolding pro-
teins. Another important question to be
addressed by future research is themolecu-
lar basis through which GPCR heteromers
affect G protein function. For example, it
has been shown that drugs that activate
the Gq/11-coupled 5-HT2A receptor induce
both Gq/11- and Gi/o-dependent signal-
ing in HEK293 cells co-expressing 5-HT2A
and the Gi/o-coupled mGlu2 receptor
as a GPCR heteromer (Gonzalez-Maeso
et al., 2008). Although findings in knock-
out mice suggest that co-expression of
5-HT2A and mGlu2 receptors is neces-
sary to activate Gq/11 and Gi/o by 5-HT2A
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agonists in mouse frontal cortex mem-
brane preparations (Fribourg et al., 2011),
whether heteromeric formation is needed
in living mice for this signaling crosstalk
remains unknown. Similarly, more work
is required both in cellulo and in animal
models to solve whether Gq/11 and Gi/o
simultaneously or sequentially couple to
the 5-HT2A-mGlu2 heteromeric receptor
complex upon agonist binding to one of
the two promoters.
Another significant limitation to our
current understanding of GPCR het-
eromeric function is the lack of knowl-
edge about physical stability of family
A GPCR heteromers in animal models.
Previous findings in HEK293 cells con-
vincingly demonstrate that the alpha1B-
adrenergic receptor forms higher-order
oligomers, and that receptor oligomeriza-
tion is required for receptor maturation
and plasma membrane delivery (Lopez-
Gimenez et al., 2007). On the other
hand, results based on an experimental
approach that recruits beta2-adrenergic
receptors into artificial domains on the
surface of living HEK293 cells suggest
that the components of family A GPCR
homomers interact transiently (Fonseca
and Lambert, 2009; Gavalas et al., 2013).
A similar conclusion has been reached
using total internal reflection fluorescence
microscopy (TIRFM) to visualize individ-
ual molecules in isolated CHO cells—the
authors observed a transient association
and dissociation of muscarinic M1 recep-
tor dimers in real time (Hern et al., 2010).
Much further work is needed to character-
ize where along the pathway from synthesis
to maturation and degradation do GPCR
heteromers form. It also remains uncer-
tain the stability of family A GPCR het-
eromers both in vitro and in whole animal
models. Many studies examining homo-
meric GPCR interfaces report that residues
of both TM1 and TM4 form symmetri-
cal interfaces that lead to higher order
species in heterologous expression systems
(Guo et al., 2005, 2008), and this has been
supported further by a number of recent
crystal structures (Wu et al., 2012; Huang
et al., 2013). However, it remains to be
fully elucidated whether different homo-
meric and heteromeric organizations (e.g.,
squares and/or parallelograms)might exist
in native tissue. These are all key questions
that require further technical advances.
In conclusion, although a range of
approaches has been applied and this
has led to a general appreciation that
GPCR heteromers affect receptor traffick-
ing, pharmacology and function in cellulo,
much more work is needed to probe the
role of GPCR heteromerization in vivo.
These advances in GPCR heteromeric
research are now occurring at a rapid pace
and promise to greatly contribute to the
future of molecular medicine.
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